加齢黄斑変性市場：タイプ別、治療法別、投与方法別、医療環境別、流通チャネル別-2025～2030年世界予測

加齢黄斑変性市場の2023年の市場規模は104億5,000万米ドルで、2024年には111億米ドルに成長し、CAGRは6.67%、2030年には164億3,000万米ドルに達すると予測されています。

加齢黄斑変性（AMD）は、医療従事者、研究者、医療産業の意思決定者にとって、ますます重要な焦点となっています。この進行性の眼疾患は、依然として世界中の高齢者の視力低下の主要原因となっています。最近の治療法の進歩、新たな技術、進行中の疫学調査により、AMDに対する理解が広がっています。このような複雑な環境において、治療選択肢、治療提供チャネル、様々な地域力学の影響を正確に評価することは、将来の戦略を形成する上で極めて重要です。

この分析では、AMDの多面的な世界を包括的に考察し、従来の臨床的視点にとどまらない議論を展開します。市場に影響を与える主要促進要因を探り、重要なセグメンテーション基準を検討し、最新の治療介入を支える進化する治療方法について明らかにします。ここでの議論は、意思決定者がAMDのエコシステムに潜む課題と潜在的な機会をより深く理解できるように設計されています。臨床検査や規制の承認が着実に治療における新たな地平を切り開く中、利害関係者は、それぞれの責任範囲における直接的な影響と長期的な影響の両方を考慮することが奨励されます。

この後のセクションでは、治療風景のダイナミックな変化、種類、治療モダリティ、提供方法、医療環境、流通チャネルなどの詳細なセグメンテーションに関する洞察、さらにこれらの動向を形成している地域や企業の貢献者について掘り下げています。これらの要素を紐解くことで、AMDの管理における戦略的計画や技術革新の可能性に役立つ専門家レベルの解説を提供しています。

加齢黄斑変性市場の変革

加齢黄斑変性の治療状況は、医療の急速な進歩と患者のニーズの進化を反映し、劇的な変化を遂げています。技術の飛躍的進歩と洗練された臨床的アプローチに後押しされ、産業は従来の治療法から、より対象を絞った個別化アプローチへの転換を目の当たりにしています。この変革は、医薬品と外科的介入の両方における革新によって特徴づけられます。

治療戦略の進化には、新規の抗炎症薬、抗VEGF薬、革新的な抗酸化剤とサプリメント製剤、新興の遺伝子治療の開発が含まれます。これらの治療法は、特に分子生物学とドラッグデリバリー技術の飛躍的進歩に照らして、患者の予後を大きく変えています。同時に、レーザー治療、黄斑転位術、光線力学的療法、先進的硝子体切除術など、精度を重視した外科的介入も進化しています。これらの介入アプローチはいずれも、手術に関連するリスクを軽減し、AMD患者の長期的な機能的転帰を向上させることを目的としています。

さらに、遠隔モニタリングやよりタイムリーな介入のためのデジタルヘルスソリューションの採用は、流動的な産業をさらに浮き彫りにしています。この変革的なシフトは、臨床結果に影響を与えるだけでなく、主要利害関係者間の市場需要や戦略的優先事項の変化をも促進します。調査、規制の変更、患者中心のイノベーションの相互作用により、産業のベテランは確立されたパラダイムを再考し、ダイナミックで患者中心の介入が将来の標準となる環境に適応するよう促されています。

AMD市場における重要なセグメンテーション洞察

AMD市場をより深く理解するには、多角的なセグメンテーションが必要です。疾患タイプを考慮する場合、市場は2つの主要カテゴリーに分類されます：乾性加齢黄斑変性と湿性加齢黄斑変性です。有病率の差と治療反応性の違いから、これらのサブタイプを詳細に比較する必要があります。

タイプによる基本的な区別にとどまらず、市場は治療方法に基づいてさらに細分化されます。主に、これらの治療アプローチは医薬品と外科的介入に分類されます。医薬品セグメント自体は、抗炎症薬、抗VEGF薬、抗酸化剤とサプリメント、遺伝子治療などのサブカテゴリーのスペクトルを包含しており、それぞれが独自の作用機序と臨床的影響を有しています。対照的に、外科的介入は、レーザー治療、黄斑転位術、光線力学的療法、硝子体手術などの確立された方法と新たな方法によって特徴づけられます。これらの介入は、リスクを最小限に抑えながら患者の転帰を向上させるよう改良されてきました。

さらに、治療は注射、硝子体内注入、経口投与などの方法で投与されます。これらの治療が提供される環境はさらに市場を細分化します。医療環境は外来手術センターから専用病院、眼科専門クリニックまでさまざまです。最後に、病院薬局、オンライン薬局、小売薬局など、これらの治療の普及を促進する流通チャネルが、さらに市場を細分化しています。このような包括的なセグメンテーションは、市場力学を理解する上で不可欠であり、利害関係者が患者の治療継続の各段階における特定のニーズに対応するためのアプローチを調整するのに役立ちます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で高齢者が増加
    • レーザー治療と抗血管新生薬の使用急増
    • AMDの効果的な検出のための診断施設と技術の増強
  • 抑制要因
    • AMDに関連する医薬品リコールの潜在的リスク
  • 機会
    • AMDに対する重要な政府施策と資金提供
    • 細胞治療と組織工学による新しい先進的治療法の導入
  • 課題
    • 厳格な規制環境と新しい治療法の複雑な承認
• 市場セグメンテーション分析
  • タイプ：ドライAMDの段階的な視力低下と急速な視力低下を個別治療で対象とする
  • 治療法：加齢黄斑変性における包括的な管理と革新的な医薬品治療
  • 投与方法：加齢黄斑変性の革新的な注入方法
  • 医療環境：先進的で費用対効果の高い治療を提供するASC、病院、クリニックを通じたAMD管理の包括的ケア
  • 流通チャネル：AMD治療を流通するオンライン薬局の急増により、包括的な患者ケアが確保される
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境
• 顧客のカスタマイズ
  • 国による治療を受けている患者数と平均治療費

第6章 加齢黄斑変性市場：タイプ別

• イントロダクション
• 乾性加齢黄斑変性
• 湿性加齢黄斑変性

第7章 加齢黄斑変性市場：治療法別

• イントロダクション
• 医薬品
  • 抗炎症薬
  • 抗VEGF薬
  • 抗酸化物質とサプリメント
  • 遺伝子治療
• 外科的介入
  • レーザー療法
  • 黄斑転座手術
  • 光線力学療法
  • 硝子体切除術

第8章 加齢黄斑変性市場：投与方法別

• イントロダクション
• 注射剤
• 硝子体内インプラント
• 経口

第9章 加齢黄斑変性市場：医療環境別

• イントロダクション
• 外来手術センター
• 病院
• 眼科クリニック

第10章 加齢黄斑変性市場：流通チャネル別

• イントロダクション
• 病院薬局
• オンライン薬局
• 小売薬局

第11章 南北アメリカの加齢黄斑変性市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の加齢黄斑変性市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの加齢黄斑変性市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Adverum BIoTechnologies, Inc.
• Alkeus Pharmaceuticals, Inc.
• Allegro Ophthalmics, LLC
• Amgen Inc.
• Annexon, Inc.
• Apellis Pharmaceuticals, Inc.
• AsclepiX Therapeutics
• Astellas Pharma Inc.
• Bausch Health Companies Inc.
• Bayer AG
• Biocon Ltd
• Biogen Inc.
• Clearside Biomedical, Inc.
• EyePoint Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.
• Formycon AG
• Grifols, S.A.
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson Services, Inc.
• Kodiak Sciences Inc.
• Lineage Cell Therapeutics, Inc.
• Lupin Limited
• Merck & Co., Inc.
• Nicox S.A.
• Novartis AG
• PanOptica, Inc.
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Sandoz Group AG
• Sun Pharmaceutical Industries, Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. AGE-RELATED MACULAR DEGENERATION MARKET MULTI-CURRENCY
• FIGURE 2. AGE-RELATED MACULAR DEGENERATION MARKET MULTI-LANGUAGE
• FIGURE 3. AGE-RELATED MACULAR DEGENERATION MARKET RESEARCH PROCESS
• FIGURE 4. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. AGE-RELATED MACULAR DEGENERATION MARKET DYNAMICS
• TABLE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTIOXIDANTS & SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GENE THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY MACULAR TRANSLOCATION SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY VITRECTOMY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTRAVITREAL IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 59. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 60. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 61. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 62. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 63. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 87. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 96. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 97. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 98. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 99. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 100. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 103. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 104. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 105. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 106. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 107. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 121. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 127. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 128. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 134. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 135. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 141. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 142. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 148. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 149. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 155. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 156. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 158. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 162. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 163. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 169. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 170. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 171. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 172. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 179. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 180. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 184. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 185. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 186. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 191. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 192. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 193. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 194. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 198. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 199. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 200. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 201. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 205. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 206. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 207. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 208. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 212. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 213. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 214. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 215. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 219. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 220. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 221. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 222. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 223. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 224. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 225. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 226. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 227. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 228. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 229. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 233. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 234. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 235. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 236. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 240. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 241. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 242. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 243. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 244. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 245. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 246. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 247. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 248. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 249. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 250. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 251. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 252. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 253. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 254. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 255. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 256. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 257. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 258. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 259. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 260. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 261. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 262. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 263. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 264. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 265. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 266. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 267. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 268. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 269. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 270. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 271. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 272. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 273. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 274. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 275. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 276. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 277. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 278. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 279. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 280. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 281. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 282. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 283. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 284. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 285. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 286. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 287. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 288. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 289. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
• TABLE 290. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 291. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 292. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 293. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
• TABLE 294. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
• TABLE 295. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 296. SWEDEN AGE-RELATED MACULAR DEGENERATION

The Age-related Macular Degeneration Market was valued at USD 10.45 billion in 2023 and is projected to grow to USD 11.10 billion in 2024, with a CAGR of 6.67%, reaching USD 16.43 billion by 2030.

Age-related Macular Degeneration (AMD) has increasingly become a central focus for medical practitioners, researchers, and decision-makers across the healthcare industry. This progressive eye condition remains a leading cause of vision loss in older adults worldwide. Recent advancements in treatment methods, emerging technologies, and ongoing epidemiological research have expanded our understanding of AMD. In this complex environment, accurately evaluating treatment options, care delivery channels, and the influence of various regional dynamics is critical to shaping future strategies.

This analysis takes a comprehensive look into the multifaceted world of AMD, where discussions extend beyond the traditional clinical perspectives. It explores key drivers affecting the market, reviews important segmentation criteria, and provides clarity on the evolving treatment modalities that underpin modern therapeutic interventions. The discussion here is designed to offer decision-makers a refined understanding of the challenges and potential opportunities that lie in the AMD ecosystem. As clinical trials and regulatory approvals steadily open up new horizons in treatment, stakeholders are encouraged to consider both immediate and long-term implications for their respective spheres of responsibility.

The subsequent sections delve into dynamic shifts in treatment landscapes, granular segmentation insights including type, treatment modality, delivery method, healthcare setting, and distribution channel, as well as the regional and corporate contributors shaping these trends. By unpacking these elements, this overview offers an expert-level narrative designed to inform strategic planning and potential areas for innovation in managing AMD.

Transformative Shifts in AMD Treatment Landscape

The treatment landscape for Age-related Macular Degeneration has experienced dramatic changes, reflecting rapid advancements in medical science and evolving patient needs. Driven by technological breakthroughs and refined clinical approaches, the industry is witnessing a shift from traditional treatment methods to more targeted and personalized approaches. This transformation is characterized by innovations in both pharmaceuticals and surgical interventions.

The evolution in treatment strategies includes the development of novel Anti-inflammatory Drugs, Anti-VEGF Agents, innovative Antioxidants & Supplements formulations, and emerging Gene Therapy Drugs. These therapies, especially in light of breakthroughs in molecular biology and drug delivery techniques, have significantly altered the prognosis for patients. Simultaneously, surgical interventions have evolved with precision-based procedures such as Laser Therapy, Macular Translocation Surgery, Photodynamic Therapy, and advanced Vitrectomy techniques. Each of these intervention approaches is designed to reduce the procedure-related risks and enhance the long-term functional outcomes for those affected by AMD.

Moreover, the adoption of digital health solutions for remote monitoring and more timely interventions further underscores an industry in flux. This transformative shift not only influences clinical outcomes but also drives changes in market demand and strategic priorities among key stakeholders. The interplay of research, regulatory changes, and patient-centric innovations is prompting industry veterans to rethink established paradigms and adapt to an environment where dynamic, patient-focused interventions are the future norm.

Critical Segmentation Insights in the AMD Market

A nuanced understanding of the AMD market requires dissecting its segmentation across multiple dimensions. When considering disease type, the market accommodates two central categories: Dry Age-Related Macular Degeneration and Wet Age-Related Macular Degeneration. The differential prevalence and the variation in therapeutic responsiveness necessitate a detailed comparison of these subtypes.

Beyond the fundamental differentiation by type, the market is further segmented based on treatment modality. Primarily, these therapeutic approaches fall into pharmaceuticals and surgical interventions. The pharmaceutical segment itself encompasses a spectrum of sub-categories including Anti-inflammatory Drugs, Anti-VEGF Agents, Antioxidants & Supplements, and Gene Therapy Drugs, each with its own distinct mechanism of action and clinical impact. In contrast, surgical interventions are characterized by established and emerging procedures such as Laser Therapy, Macular Translocation Surgery, Photodynamic Therapy, and Vitrectomy. These interventions have been refined to enhance patient outcomes while minimizing risks.

In addition, delivery methods play a critical role in segmentation, with therapeutic agents being administered through injectable methods, intravitreal implants, or oral routes. The context within which these treatments are delivered further segments the market; healthcare settings vary from Ambulatory Surgical Centers to dedicated Hospitals and specialized Ophthalmology Clinics. Lastly, the distribution channels that facilitate the reach of these treatments-whether through Hospital Pharmacies, Online Pharmacies, or Retail Pharmacies-add yet another layer of detail. Such comprehensive segmentation is essential to understanding market dynamics and assists stakeholders in tailoring their approaches to address the specific needs at every step of the patient care continuum.

Based on Type, market is studied across Dry Age-Related Macular Degeneration and Wet Age-Related Macular Degeneration.

Based on Treatment Modality, market is studied across Pharmaceuticals and Surgical Interventions. The Pharmaceuticals is further studied across Anti-inflammatory Drugs, Anti-VEGF Agents, Antioxidants & Supplements, and Gene Therapy Drugs. The Surgical Interventions is further studied across Laser Therapy, Macular Translocation Surgery, Photodynamic Therapy, and Vitrectomy.

Based on Delivery Method, market is studied across Injectable, Intravitreal implants, and Oral.

Based on Healthcare Setting, market is studied across Ambulatory Surgical Centers, Hospitals, and Ophthalmology Clinics.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Regional Insights Shaping AMD Market Trends

Regional dynamics play an influential role in the evolution of the AMD market, as variations in demographics, economic development, and healthcare infrastructure across different regions profoundly affect both access and treatment outcomes. In the Americas, robust healthcare systems and significant investment in research and development have spurred the early adoption of new technologies. This region's emphasis on advanced diagnostic techniques and personalized treatments is driving market growth and setting benchmarks for clinical innovation.

At the same time, the combined regions of Europe, the Middle East, and Africa showcase a diverse array of market conditions. Europe benefits from traditionally strong pharmaceutical research and a steady market for advanced therapies whereas both the Middle East and Africa are increasingly embracing modern healthcare practices. Despite the disparities in resource allocation, these regions are progressively adopting new treatment methodologies and integrating innovative supply chain solutions to improve access to care for AMD patients.

In Asia-Pacific, rapid economic development coupled with a rising elderly population has created a fertile ground for market expansion. The region is notable for its increasing investments in healthcare infrastructure and concerted efforts toward the adoption of cutting-edge diagnostic and treatment modalities. Emphasis on scalable, cost-effective solutions and robust public-private partnerships further propels the growth trajectory within these emerging markets. Collectively, these regional insights underscore the importance of geographic diversity in the strategic planning of AMD interventions and signal distinct opportunities for tailored market approaches.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights Driving Innovation in AMD Solutions

The AMD market is influenced by a cadre of leading companies whose innovations and strategic developments are shaping treatment paradigms. Notable industry pioneers such as AbbVie Inc. and Adverum Biotechnologies, Inc. have been trailblazers in advancing biopharmaceutical applications, playing a critical role in the promotion of next-generation therapies. Equally important are firms like Alkeus Pharmaceuticals, Inc. and Allegro Ophthalmics, LLC, whose research in novel drug formulations and surgical protocols have redefined the standards of care.

Other key players including Amgen Inc. and Annexon, Inc. have contributed significantly to the evolution of treatment efficacy and patient safety. Apellis Pharmaceuticals, Inc. and AsclepiX Therapeutics bring fresh perspectives to the market through progressive clinical developments, while Astellas Pharma Inc. and Bausch Health Companies Inc. provide vital market stability with their established portfolios. Bayer AG and Biocon Ltd further complement this ecosystem by driving collaborative research initiatives that bridge the gap between clinical research and practical application.

In addition, Biogen Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., and F. Hoffmann-La Roche Ltd. are at the forefront of integrating technological advancements in treatment delivery. The insights provided by companies such as Formycon AG, Grifols, S.A., Ionis Pharmaceuticals, Inc., and Johnson & Johnson Services, Inc. highlight the continuous interplay of innovation and clinical utility. Kodiak Sciences Inc., Lineage Cell Therapeutics, Inc., and Lupin Limited position themselves as early adopters of transformational treatment modalities, while industry leaders like Merck & Co., Inc., Nicox S.A., Novartis AG, PanOptica, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sandoz Group AG, Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. round out a comprehensive list of pioneers driving forward the future of AMD treatments. These companies not only lead in research and development but also actively shape market dynamics through strategic alliances and continuous innovation.

The report delves into recent significant developments in the Age-related Macular Degeneration Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adverum Biotechnologies, Inc., Alkeus Pharmaceuticals, Inc., Allegro Ophthalmics, LLC, Amgen Inc., Annexon, Inc., Apellis Pharmaceuticals, Inc., AsclepiX Therapeutics, Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, Biocon Ltd, Biogen Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Formycon AG, Grifols, S.A., Ionis Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Kodiak Sciences Inc., Lineage Cell Therapeutics, Inc., Lupin Limited, Merck & Co., Inc., Nicox S.A., Novartis AG, PanOptica, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sandoz Group AG, Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to capitalize on emerging technological innovations and evolving market dynamics to maintain a competitive edge. Evaluating the potential of next-generation therapeutics and novel drug delivery systems is paramount to driving improved patient outcomes. Decision-makers should prioritize research investments in both pharmaceutical and surgical domains, particularly in areas that promise reduced adverse effects and enhanced efficacy.

Leaders must also consider expanding healthcare infrastructure by integrating multi-channel distribution strategies. By bridging gaps between hospitals, ambulatory centers, and online platforms, stakeholders can ensure improved access to advanced treatment modalities. Strategic collaborations among research institutions, private enterprises, and regulatory bodies will be essential to facilitate faster adoption of breakthroughs. Tactical market segmentation analysis - including disease subtypes, treatment methods, and regional specifics - plays a critical role in identifying gaps and untapped opportunities. A proactive approach that blends investment in innovation with adaptive operational strategies will enable organizations to respond more effectively to the evolving landscape and better serve patients in a competitive market.

Conclusion and Future Outlook in AMD

The comprehensive review of the Age-related Macular Degeneration market reveals a dynamic environment marked by robust innovations, significant geographical variances, and an evolving list of key players. As transformative shifts in both pharmaceutical and surgical treatments redefine traditional practices, the opportunity for breakthroughs is more imminent than ever. The layered segmentation, spanning disease type, modality, administration method, healthcare setting, and distribution channels, provides valuable insights that can inform targeted strategic initiatives.

This analysis underscores the necessity for a forward-thinking approach that integrates technological advancements with strategic operational planning. Looking ahead, continued progress in the development of patient-centric therapies, heightened awareness across regional markets, and collaborative innovation among industry leaders hold the promise of enhanced outcomes for AMD patients. The future within this sector is promising, with the sustained potential for improved diagnostic and treatment options, which collectively pave the way for a more accessible and effective healthcare ecosystem.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing number of geriatric population across the world
    • 5.1.1.2. Surging use of laser therapy and anti-angiogenesis drugs
    • 5.1.1.3. Increasing diagnostics facilities and technology for effective detection of AMD
  • 5.1.2. Restraints
    • 5.1.2.1. Potential risk of drug recalls associated with AMD
  • 5.1.3. Opportunities
    • 5.1.3.1. Significant government policies & funding for AMD
    • 5.1.3.2. Introduction of novel and advanced treatments based on cell therapy and tissue engineering
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory environment and complex approval of new treatments
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Targeting gradual vision loss in dry AMD and rapid impairment with tailored treatments
  • 5.2.2. Treatment: Comprehensive management and innovative pharmaceutical treatments in age-related macular degeneration
  • 5.2.3. Delivery Method: Innovative injectable methods for age-related macular degeneration
  • 5.2.4. Healthcare Setting: Comprehensive care in AMD management through ASCs, hospitals, and clinics with advanced and cost-effective treatments
  • 5.2.5. Distribution Channel: Proliferation of online pharmacies for distributing AMD drugs to ensure comprehensive patient care
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization
  • 5.5.1. Number of Patients Undergoing Treatments and Average Cost of Treatment By Country

6. Age-related Macular Degeneration Market, by Type

• 6.1. Introduction
• 6.2. Dry Age-Related Macular Degeneration
• 6.3. Wet Age-Related Macular Degeneration

7. Age-related Macular Degeneration Market, by Treatment Modality

• 7.1. Introduction
• 7.2. Pharmaceuticals
  • 7.2.1. Anti-inflammatory Drugs
  • 7.2.2. Anti-VEGF Agents
  • 7.2.3. Antioxidants & Supplements
  • 7.2.4. Gene Therapy Drugs
• 7.3. Surgical Interventions
  • 7.3.1. Laser Therapy
  • 7.3.2. Macular Translocation Surgery
  • 7.3.3. Photodynamic Therapy
  • 7.3.4. Vitrectomy

8. Age-related Macular Degeneration Market, by Delivery Method

• 8.1. Introduction
• 8.2. Injectable
• 8.3. Intravitreal implants
• 8.4. Oral

9. Age-related Macular Degeneration Market, by Healthcare Setting

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
• 9.3. Hospitals
• 9.4. Ophthalmology Clinics

10. Age-related Macular Degeneration Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Americas Age-related Macular Degeneration Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Age-related Macular Degeneration Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Age-related Macular Degeneration Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Genentech relaunches Susvimo for wet AMD with improved vision
  • 14.3.2. Stealth BioTherapeutics launches phase 3 trial for elamipretide to combat dry age-related macular degeneration and improve patient outcomes
  • 14.3.3. LambdaVision secures funding to advance preclinical trials of innovative artificial retina
  • 14.3.4. Science Corporation acquires Pixium Vision's PRIMA retinal implant to enhance vision restoration for AMD patients
  • 14.3.5. Researchers at HKUMed develop groundbreaking photoactivatable nanomedicine for safer and more effective age-related macular degeneration treatment
  • 14.3.6. EyeBio secures USD 130 million Series A funding to advance Restoret therapy for age-related macular degeneration treatment
  • 14.3.7. Astellas Pharma unveils treatment for age-related macular degeneration with promising efficacy and safety results
  • 14.3.8. FDA provides clearance of clinical trials for Aviceda Therapeutics' AVD-104 targeting age-related macular degeneration
  • 14.3.9. Retinal Degeneration Fund's major investment boosts biotech to advance age-related macular degeneration treatments and improve quality of life
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. F. Hoffmann-La Roche Ltd.
  • 14.4.2. Novartis AG
  • 14.4.3. Bayer AG
  • 14.4.4. Astellas Pharma Inc.

Companies Mentioned

• 1. AbbVie Inc.
• 2. Adverum Biotechnologies, Inc.
• 3. Alkeus Pharmaceuticals, Inc.
• 4. Allegro Ophthalmics, LLC
• 5. Amgen Inc.
• 6. Annexon, Inc.
• 7. Apellis Pharmaceuticals, Inc.
• 8. AsclepiX Therapeutics
• 9. Astellas Pharma Inc.
• 10. Bausch Health Companies Inc.
• 11. Bayer AG
• 12. Biocon Ltd
• 13. Biogen Inc.
• 14. Clearside Biomedical, Inc.
• 15. EyePoint Pharmaceuticals, Inc.
• 16. F. Hoffmann-La Roche Ltd.
• 17. Formycon AG
• 18. Grifols, S.A.
• 19. Ionis Pharmaceuticals, Inc.
• 20. Johnson & Johnson Services, Inc.
• 21. Kodiak Sciences Inc.
• 22. Lineage Cell Therapeutics, Inc.
• 23. Lupin Limited
• 24. Merck & Co., Inc.
• 25. Nicox S.A.
• 26. Novartis AG
• 27. PanOptica, Inc.
• 28. Pfizer Inc.
• 29. Regeneron Pharmaceuticals, Inc.
• 30. Sandoz Group AG
• 31. Sun Pharmaceutical Industries, Ltd.
• 32. Teva Pharmaceutical Industries Ltd.
• 33. Viatris Inc.